{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"Phase 1: to determine the MTD of panobinostat (LBH589) in combination with melphalan to be used in the Phase 2 portion of the study","groups":[{"description":"20mg daily LBH589 and 0.05mg/kg melphalan on days 1, 3 and 5 of week 1","id":"OG000","title":"Melphalan and Panobinostat Schedule D3"}],"paramType":"NUMBER","populationDescription":"MTD for Melphalan and Panobinostat was reached in the cohort of 6 participants who received 20 mg/daily LBH589 PO and melphalan PO at 0.05 mg/kg on days 1, 3 and 5 of week 1 of each cycle. Three additional patients were enrolled as part of the phase 2 expansion.","reportingStatus":"POSTED","timeFrame":"12 months","title":"Maximum Tolerated Dose (MTD)","type":"PRIMARY","unitOfMeasure":"mg LBH589"}